iBio, Inc. Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2021; filed May 17, 2021. The supplied metadata identifies “2020 Q3,” but the filing is for fiscal Q3 2021.
Business Context
iBio is a biotechnology company and biologics contract development and manufacturing organization. Its activities include therapeutics and vaccine development, FastPharming-based CDMO services, Glycaneering services, and research and bioprocess products. During the second half of fiscal 2020 and thereafter, management shifted its primary focus toward biologics development, including vaccines and therapeutics, while continuing CDMO operations.
Financial Results and Position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $0.765 million, versus $0.096 million | $1.880 million, versus $0.518 million |
| Gross profit | $0.272 million, versus $0.010 million | $0.605 million, versus $0.114 million |
| Gross margin | 35.6%, versus 10.4% | 32.2%, versus 22.0% |
| Operating loss | $7.203 million, versus $4.064 million | $21.672 million, versus $11.074 million |
| Net loss attributable to iBio stockholders | $7.725 million, or $0.04 per share | $23.518 million, or $0.12 per share |
| Net cash used in operating activities | Not presented for the quarter | $22.838 million, versus $9.478 million |
- R&D expense increased to $2.162 million for the quarter and $6.892 million for the nine months, primarily due to personnel and other costs supporting proprietary therapeutics and vaccines.
- G&A expense increased to $5.313 million for the quarter and $15.385 million for the nine months, primarily due to higher headcount and consulting costs.
- Cash and cash equivalents were $84.627 million at March 31, 2021, compared with $55.112 million at June 30, 2020. Investments in debt securities were $19.296 million, producing total cash and debt securities of approximately $103.9 million.
- Total assets were $142.697 million and total liabilities were $37.867 million at March 31, 2021. Accumulated deficit was $173.743 million.
- Debt consisted primarily of a $32.084 million finance lease obligation, including $31.766 million non-current, and a $0.600 million PPP loan. The finance lease has a 34-year term and requires minimum future payments of $79.750 million, including $47.666 million of interest.
- Financing activities provided $75.923 million during the nine months, principally from common-stock offerings. Investing activities used $23.570 million, including purchases of debt securities and fixed-asset investment.
Material Changes Versus the Prior Comparable Period
- Revenue increased 697% for the quarter and 263% for the nine months, reflecting completion of a small number of larger, higher-margin CDMO projects. One customer represented 92% of quarterly revenue.
- Gross margin improved substantially, but operating losses widened because operating expenses increased faster than revenue.
- Quarterly and nine-month losses were lower on a per-share basis than in the prior periods, partly because the prior-year nine-month loss included a $21.560 million deemed dividend related to down-round features of preferred stock.
- Common shares outstanding increased to 216.1 million at March 31, 2021 from 140.1 million at June 30, 2020, reflecting substantial equity financing and conversion of Series B Preferred Stock. Further dilution remains possible.
- The company reclassified certain operating expenses to separately present cost of goods sold, R&D, and G&A. Management characterized the correction as immaterial; it did not affect operating loss, net loss, cash flow, or earnings per share.
Guidance, Outlook, Risks, and Unusual Items
- Management believes existing cash and debt securities will fund activities through March 31, 2023, but expects continued losses, negative operating cash flow, and increasing expenses as product development advances.
- Planned spending includes IND-enabling studies for IBIO-100 in fiscal 2022, further development of IBIO-400, expansion of drug-discovery capabilities in San Diego, and potential clinical development activities.
- The company expects to require additional funding over time. Future equity financing could materially dilute shareholders, and funding may not be available on acceptable terms.
- On May 4, 2021, iBio settled its Fraunhofer litigation. The settlement provides for $28 million of cash payments, including $16 million expected by May 14, 2021 and additional payments in 2022 and 2023. After legal, litigation-funding, and related costs, management estimated aggregate net cash recovery of approximately $12 million. The filing does not establish that all payments had been received as of the filing date.
- The settlement also grants iBio a nonexclusive, nontransferable, worldwide, fully paid-up license to specified Fraunhofer plant-based technology and releases the parties’ claims and counterclaims.
- iBio reported that IBIO-201 completed IND-enabling toxicology studies without identified adverse effects at tested doses and that preclinical studies for IBIO-202 were initiated. These programs remain preclinical and require further development and regulatory progress.
- COVID-19 previously reduced CDMO capacity and caused a three-day facility shutdown. Future pandemic effects remain uncertain.
- The company relies on licenses, including the University of Pittsburgh license for IBIO-100. The license includes development milestones, including an IND filing deadline of December 31, 2021; failure to meet milestones could jeopardize the license.
- At March 31, 2021, only approximately 23.5 million common shares were available for issuance after outstanding reservations. The company may seek authorization for additional shares or a reverse stock split, but a prior proposal to increase authorized shares was not approved.
- The PPP loan had not yet been submitted for forgiveness as of the filing date; forgiveness remained subject to SBA approval and documentation requirements.
Most Important Facts to Verify
- Whether the initial $16 million Fraunhofer settlement payment was received and the resulting net cash benefit after legal and funding costs.
- Actual quarterly and annualized cash burn relative to management’s March 31, 2023 liquidity estimate.
- CDMO customer concentration, backlog, project margins, and sustainability of the recent revenue increase.
- Progress toward the University of Pittsburgh license milestones, particularly the IBIO-100 IND deadline.
- Regulatory and preclinical progress for IBIO-201, IBIO-202, IBIO-100, and IBIO-400.
- Potential dilution from the remaining equity program, stock options, restricted stock units, and any increase in authorized shares.
- Status of PPP loan forgiveness and obligations under the long-term related-party finance lease.